Can a smarter scan spot breast cancer treatment failure faster?
NCT ID NCT07130344
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares two types of scans—standard CT and bone scans versus PET-CT—to see which better evaluates how well the drug trastuzumab deruxtecan (T-DXd) works in people with HER2 low metastatic breast cancer. About 262 participants will be split into two groups and scanned every 3 months. The goal is to find out if PET-CT can identify non-responders earlier, potentially avoiding unnecessary side effects and costs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan (T-DXd)
What this could lead to
If successful, this could show that PET-CT scans detect treatment response earlier than standard CT scans, helping doctors avoid ineffective treatments sooner.
What could go wrong
This is an observational imaging study, not testing a new drug. The results may not change practice if PET-CT doesn't prove clearly better than standard scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICANS
Strasbourg, 67033, France
Contact Phone: •••-•••-•••• Email: •••••@•••••